The development of drugs targeting the brain still faces a high failure rate. One of the reasons is a lack of quantitative understanding of the complex processes that govern the pharmacokinetics (PK) of a drug within the brain. While a number of models on drug distribution into and within the brain is available, none of these addresses the combination of factors that affect local drug concentrations in brain extracellular fluid (brain ECF). Here, we develop a 3D brain unit model, which builds on our previous proof-of-concept 2D brain unit model, to understand the factors that govern local unbound and bound drug PK within the brain. The 3D brain unit is a cube, in which the brain capillaries surround the brain ECF. Drug concentration-time profiles are described in both a blood-plasma-domain and a brain-ECF-domain by a set of differential equations. The model includes descriptions of blood plasma PK, transport through the blood-brain barrier (BBB), by passive transport via paracellular and trancellular routes, and by active transport, and drug binding kinetics. The impact of all these factors on ultimate local brain ECF unbound and bound drug concentrations is assessed. In this article we show that all the above mentioned factors affect brain ECF PK in an interdependent manner. This indicates that for a quantitative understanding of local drug concentrations within the brain ECF, interdependencies of all transport and binding processes should be understood. To that end, the 3D brain unit model is an excellent tool, and can be used to build a larger network of 3D brain units, in which the properties for each unit can be defined independently to reflect local differences in characteristics of the brain.
all of the above mentioned factors affect drug concentrations within brain ECF in an interdependent manner. The 3D brain unit model that we have developed is an excellent tool to increase our understanding of how local drug concentrations within the brain ECF are affected by brain transport and binding processes. considered the smallest physiological unit of the brain in terms of drug transport. 47 Within the 3D brain unit, drug is carried along with the blood plasma by the brain 48 capillary blood flow and as such presented to the brain ECF. Drug distributes between 49 the blood plasma and the brain ECF by transport across the BBB. Thereafter, drug 50 distribution within the brain ECF is affected by diffusion, bulk flow and binding. We 51 describe the distribution of drug within the brain ECF by a partial differential equation 52 (PDE) and couple this to two ordinary differential equations (ODEs) to account for 53 specific and non-specific drug binding. 54 The model builds on a proof-of-concept 2D brain unit model [29] . The 2D model is a 55 basic model covering many essential aspects of drug distribution within the brain, 56 including passive BBB transport, diffusion, brain ECF bulk flow, specific binding of a 57 drug at its target site and non-specific binding of a drug to components of the brain. 58 Here, brain cells are implicitly implemented by describing the hindrance the cells 59 impose on the transport of a drug within the brain ECF in a tortuosity term. This 60 model has enabled the study of the effect of drug properties and brain tissue 61 characteristics on the distribution of a drug within the brain ECF and on its specific 62 and non-specific binding behaviour of the drug. 63 The current 3D brain unit model further improves the prediction of drug distribution 64 within the brain. The third dimension improves the realistic features of the model as 65 the brain is also 3D. Then, the brain capillary blood flow and active transport across 66 the BBB, which are both important mechanisms of drug transport into the brain, are 67 included. Here, we focus on one single brain unit. This allows for a thorough 68 characterisation of drug distribution within one 3D brain unit before expanding to a 69 larger scale. 70 In the remainder of this article, the mathematical representation of the characteristics 71 of the 3D brain unit is introduced (section 2). There, we formulate the model (section 72 2.1) and the mathematical descriptions of the drug distribution within the blood plasma 73 of the brain capillaries (section 2.2) and within the brain (section 2.3). In section 2.4 we 74 formulate the model boundary conditions that describe drug exchange between the 75 blood plasma and the brain ECF by passive and active BBB transport, as well as drug 76 transport at the boundaries of the unit. In section 3, we study the effect of several 77 factors on drug distribution within the brain ECF. In section 3.1, we evaluate the effect 78 of the brain capillary blood flow velocity on local brain ECF PK in the 3D brain unit. 79 Next, we evaluate the effect of active influx and efflux on local brain ECF PK (section 80 3.2). Then, in section 3.3 we show how the interplay between the brain capillary blood 81 flow velocity, passive BBB permeability and active transport affects drug concentrations 82 within the 3D brain unit. Finally, in section 4 we conclude our work and discuss future 83 perspectives. 84 2 The 3D brain unit 85 The 3D brain unit represents the smallest piece of brain tissue that contains all 86 physiological elements of the brain. The 3D brain unit is part of a larger network of 3D 87 brain units, but here we focus on just one 3D brain unit that is fed by an arteriole and 88 drained by a venule (Fig 1, left) . The 3D brain unit is a cube in which the brain Sketch of the 3D model brain unit. Left: The structure represented by the 3D brain unit. An arteriole carries blood plasma (containing drug) into a brain capillary bed, that is connected to a venule that drains the blood plasma. The brain capillaries (red) surround the brain ECF (blue). Middle: the 3D brain unit and its sub-domains. The unit consists of a brain-ECF-domain (blue) and a blood-plasma-domain (red). The blood-plasma-domain is divided into several subdomains: U in is the domain where the dose of absorbed drug enters the 3D brain unit, U x1-x4, U y1-y4 and U z1-z4 are the domains representing the x-directed, y-directed and z-directed capillaries, respectively. Right: Directions of transport in the model. The drug enters the brain capillaries in U in. From there, it is transported through the brain capillaries by the brain capillary blood flow in the direction indicated by the small arrows. Drug in the brain capillary blood plasma exchanges with the brain ECF by crossing the BBB. Drug within the brain ECF is, next to diffusion, transported along with brain ECF bulk flow (indicated by the bold arrow). middle) has a blood-plasma-domain (red) consisting of multiple sub-domains. These 97 include the brain capillary domain where drug enters the unit (indicated by U in in Fig 98  1) , the domains representing the x-directed, y-directed and z-directed brain capillaries 99 (indicated by U x1−x4 , U y1−y4 and U z1−z4 in Fig 1) and the brain capillary domain where 100 drug leaves the unit (indicated by U out in Fig 1) . Drug within the blood plasma is 101 transported by the brain capillary blood flow. The brain capillary blood flow splits at 102 the vertices of the unit, where brain capillary branching occurs (Fig 1, right) .
103
In developing the model, we make the following assumptions about drug distribution 104 within the brain capillaries: 105 Assumptions 1.
106
(i) The drug concentration within the blood plasma changes over time as a function of 107 the rates of absorption (in case of oral administration) and elimination into and from 108 the blood plasma.
109
(ii) The blood carrying the drug flows into 3D brain unit by a feeding arteriole and 110 leaves via a draining venule (Fig 1, left) .
111
(iii) The drugs enters the brain unit in the domain U in (Fig 1, middle) .
112
(iv) The brain capillary blood flow is directed away from U in (Fig 1, right) .
113
(v) Diffusion within the blood plasma is negligible compared to the brain capillary blood 114 flow, hence drug is transported through the brain capillaries solely by the brain capillary 115 blood flow.
116
(vi) The brain capillaries are all equal in size and surface area. In addition, we assume 117 that the volume of the incoming arteriole equals the volume of the three outgoing brain 118 capillaries it connects to and that the volume of the outgoing venule equals the volume of 119 the three incoming brain capillaries it connects to. Consequently, as the total volume of 120 incoming blood vessels equals the total volume of outgoing blood vessels at each vertex 121 (see Fig 1, left) , the brain capillary blood flow velocity is by default equal in all brain 122 capillaries.
123
(vii) Drug within the blood plasma does not bind to blood plasma proteins. All drug 124 within the blood plasma is in an unbound state and is able to cross the BBB.
125
Drug within the blood plasma of the brain capillaries crosses the BBB to exchange with 126 the brain ECF. The BBB is located at the border between the brain capillaries (red) Fig 2. Front view of the 3D brain unit. Definitions of U pl are given. The x-directed, y-directed and z-capillaries are divided by the lines x=y (or y=z or x=z) and x+y=yr (or y+z=zr or x+z=zr). The only exceptions for this are the brain capillaries adjacent to U in and the brain capillaries adjacent to U out. bold arrow in Fig 1 (right) .
137
(iv) All drug distributes within the brain ECF and we only have extracellular binding 138 sites.
139
(v) The total concentration of specific and non-specific binding sites is constant.
140
(vi) The specific and non-specific binding sites are evenly distributed over the 3D brain 141 unit and do not change position.
142
(vii) The specific and non-specific binding sites lie on the outside of cells and the drug 143 does not have to cross cell membranes in order to bind to binding sites. The 3D brain unit is a cubic domain, U, that represents a piece of brain tissue. We
There, x r , y r and z r are 149 constants that represent the length of one unit, which is then defined as d cap +2r, with 150 d cap the distance between the brain capillaries and r the brain capillary radius. In one 151 brain unit, the brain capillaries, the BBB and the brain ECF are represented by the 152 subsets U pl ⊂U, U BBB ⊂U and U ECF ⊂U, respectively, such that U =U pl ∪ U BBB ∪ 153 U ECF .
154
Within U pl , we define U in as the domain where the blood plasma, containing drug, 155 enters the 3D brain unit from a feeding arteriole. We define U out as the domain where 156 the blood plasma, containing drug, leaves the 3D brain unit to a draining venule.
Here, C pl is the concentration of unbound drug in the blood plasma, C ECF is the 186 concentration of unbound drug in the brain ECF, B 1 is the concentration of drug in the 187 brain ECF bound to specific binding sites and B 2 is the concentration of drug in the 188 brain ECF bound to non-specific binding sites. Based on assumption 1(i), we define the concentration of (unbound) drug within U in by 191 including parameters related to oral administration [30] :
, where F is the bioavailability of the drug, k a the absorption rate constant of the drug, 193 k e the elimination rate constant of the drug, Dose the molar amount of orally 194 administered drug, and V d the distribution volume, which relates the total amount of 195 drug in the body to the drug concentration in the blood plasma. We focus on oral 196 administration but can also study other choices.
197
Additionally, based on assumptions 1(iv) and 1(v), we define:
, with v blood the blood flow velocity within the brain capillaries and where the initial 199 condition is given by 200 C pl (x, y, z, t = 0) = 0.
Description of drug distribution in U ECF

201
Based on assumptions 2, we describe the distribution of unbound and bound drug 202 within U ECF with the following system of equations:
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with initial conditions 204 C ECF (x, y, z, t = 0) = 0 (7)
, 205 B i (x, y, z, t = 0) = 0, i = 1, 2
, where D is the diffusion coefficient in a free medium, λ the tortuosity, v ECF the 206 (x-directed) brain ECF bulk flow, B 1 max ,the total concentration of specific binding sites 207 within the brain ECF, k 1on the association rate constant for specific binding, k 1off the 208 dissociation rate constant for specific binding, B 2 max the total concentration of 209 non-specific binding sites within the brain ECF, k 2on the association rate constant for 210 non-specific binding and k 2off the dissociation rate constant for non-specific binding. 211 
Boundary conditions 212
We formulate boundary conditions that describe the change in concentration of drug at 213 the boundary between the blood-plasma-domain (U ok ) and the brain-ECF-domain 214 (U ECF ), hence at U BB as well as at the boundaries of the 3D brain unit (U pl ∩∂ U,
215
U ECF ∩∂U ). We describe diffusive transport by the difference in drug concentrations in C ECF and 218 C pl , multiplied by the BBB permeability, P. In addition, we model active transport into 219 and out of the brain ECF with Michaelis-Menten kinetics, similar to the approach of [6] . 220 In total, this leads to:
, with u = C pl , v= C ECF , P trans being the permeability through the brain endothelial 222 cells, f trans the fraction of the area occupied by the brain endothelial cells, D para the 223 diffusivity of a drug across the paracellular space, W PCS the width of the paracellular 224 space, f para the fraction of area occupied by the paracellular space, T m-in the maximum 225 rate of drug active influx, T m-out the maximum rate of drug active efflux, K m-in the 226 concentration of drug at which half of T m-in is reached, K m-out the concentration of 227 drug at which half of T m-out is reached and SA BBB the surface area of the BBB.
228
Based hereon, we describe the loss or gain of unbound drug in the brain ECF due to 229 BBB transport with the following boundary conditions (only those for the x direction 230 are given, the ones for the y and z directions are similar):
For the blood-plasma-domain, U pl , we use the reverse of (12) to describe drug transport 232 across the BBB in the brain capillaries with the following boundary conditions:
June 24, 2019 7/23 2.4.2 Drug exchange at the faces of the 3D brain unit 234 We use additional boundary conditions to describe the drug concentrations at the sides 235 of the domain. Since we assume that there is no diffusion in the blood plasma (see 236 assumption 1(v)), we use the following boundary conditions:
, for (x,y,z) ∈ pl \ U out ∩∂ U, for x=0 and x=x r ,
, for (x,y,z) ∈ U pl \ U out ∩∂ U, for y=0 and y=y r ,
, , for (x,y,z) ∈ pl \ U out ∩∂ U, for z=0 and z=z r .
240
In addition, we define:
, for (x,y,z) ∈ U out ∩∂ U. 242 We formulate the condition at the boundaries of the 3D brain unit as follows:
, for U ECF ∩∂ U. 244 
Model parameter values and units 245
The dimensions of the 3D brain unit are based on the properties of the rat brain. The 246 model is suitable for data from human or other species as well, but we have chosen for 247 the rat as for this species most data is available. The distance between the brain 248 capillaries in the rat brain is on average 50 µm, while the brain capillaries have a radius 249 of about 2.5 µm [31] [32] [33] [34] . Therefore, we set the radius of the brain capillaries, r, to 2.5 250 µm and the dimensions of the 3D brain unit in the x, y and z directions, x r , y r and z r 251 respectively, to 55 µm.
252
In our model, we use Eq (2)-(6) to describe drug concentration within the blood plasma, 253 with boundary conditions described in Eq (13)- (17) . We describe the concentration of 254 drug within the brain ECF with Eq (7)-(9) with boundary conditions described in 255 (11), (12) and (18) . The range of values we use for the parameters in the model as well 256 as their units are given in Table 1 below. This range is based on values found in the 257 literature (from experimental studies), which we also give in the earlier articles that assume that drug binding to specific binding sites is stronger than to 261 non-specific binding sites, while non-specific binding sites are more abundant [29, 35, 36] . 262 3 Model results 263 We study the distribution of a drug within the 3D brain unit by plotting its 264 concentration-time profiles within the brain ECF (brain ECF PK). In addition, we Table 1 . 3D brain unit model parameters and their units, for rat brain. The physiological range of values of the parameters is given. These are based on references from the literature.
Parameter Unit
Range of values Ref.
F, bioavailability -0-1 [30] Dose µmol 10 -1 -10 2 V, distribution volume L 0.05-5 [38] k a , absorption rate constant
[38] [20] k e , elimination rate constant
[38] [20] d cap , intercapillary distance m 2·10 -5 -7·10 -5
[31] [39] r, brain capillary radius m 0.8-4.8·10 -6
[39] [34] v blood , brain capillary blood flow
[42] [43] P, 3D passive BBB permeability 1 m s -1 10 -10 -10 -5
K m-in , concentration needed to reach half of T m-in µmol L -1 10 1 -10 4 [46] T m-out , maximal active efflux rate µmol s -1 10 -8 -10 -5 [45] K m-out , concentration needed to reach half of T m-out µmol L -1 10 1 -10 4 [46] SA BBB surface area of the BBB 6 m 2 1.25·10 -10 B 1 max , total concentration specific binding sites 6 This is the surface area of the BBB that separates one side of a brain capillary within the 3D brain unit from the brain ECF.
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Parameter Unit Value
study the distribution of the drug within the 3D brain unit. We first nondimensionalise 266 the system of equations and boundary conditions by scaling all variables by a 267 characteristic scale, see S1 Appendix for details. Next, in order to perform simulations, 268 we discretise the nondimensionalised system spatially, using a well-established numerical 269 procedure based on finite element approximations [37] . We present the results using the 270 parameters with dimensions. The output of the simulations are the concentrations of 271 free, specifically bound and non-specifically bound drug, given in µmol L -1 over time (s). 272 The model can easily be used to study a specific drug by choosing the parameter values 273 that are specific for this drug, provided that parameter values for this drug are known. 274 In the present study, however, we choose to study generic parameter values that are in 275 the middle of the physiological ranges given in Table 1 . This allows us to perform a 276 sensitivity analysis and study the effect of parameter values at both extremes of the 277 physiological range on the behaviour of the model. We use, unless otherwise indicated, 278 the parameter values that are given in Table 2 . In the following sections, we show the 279 impact of the brain capillary blood flow velocity (v blood ) in the absence of active Table 2 . The insets in each sub-figure show the PK for a shorter time.
3.1
The effect of the brain capillary blood flow velocity on 289 brain ECF PK within the 3D brain unit 290 The impact of the brain capillary blood flow velocity, v blood , on brain ECF PK within 291 the 3D brain unit is evaluated. Parameters are as in Table 2 and we thus assume that 292 there is no active transport, i.e. T m-in =0 and T m-out =0. Here, we focus on the effect of 293 v blood on brain ECF PK in the middle of the 3D brain unit. We show the 294 concentration-time profiles of unbound, specifically bound and non-specifically bound 295 drug (C ECF , B 1 and B 2 , respectively) within the 3D brain unit on a larger time-scale, 296 for several values of v blood . We do so for the default value of the passive permeability P 297 (P =0.1·10 -7 m s -1 ), in Fig 3 (left) , as well as for a high value of P (P =100·10 -7 m s -1 ), 298 in Fig 3 (right) . The lowest value of v blood is outside the known physiological ranges 299 (see Table 1 ), but we choose it as v blood is predicted to mostly impact drug 300 concentrations in the brain when P is much higher than v blood [64, 65] . The total 301 passive permeability, P, includes both transcellular and paracellular permeability. The 302 paracellular space may increase due to disruption of the tight junctions in certain 303 disease conditions, thereby allowing larger molecules to pass through and increasing 304 paracellular transport [66, 67] . We can tune our model and separate between 305 transcellular and paracellular transport, as we do in S2 Appendix. In the current 306 section we proceed with the total passive BBB permeability. 
312
The effects of P on drug concentrations within the brain ECF are similar to those found 313 with our proof-of-concept 2D model [29] : for a high value of P, the attained values of 314 C ECF and B 2 are higher and follow C pl , while their decay is faster than for a low value 315 of P. In addition, the ≥90% maximum value of B 1 , i.e. values of B 1 that are more than 316 90% of the maximum value attained during the simulation (B 1 ≥90% max(B 1 )), is 317 attained shorter for a high value of P than for a low value of P.
318
From the results shown in Fig 3 we conclude that the effects of v blood on brain ECF PK 319 are minimal. According to the Renkin-Crone equation [64, 65] , the brain capillary blood 320 flow affects drug influx, depending on the permeability of the BBB. This is also 321 demonstrated by our model, and we show that v blood affects drug influx across the BBB 322 in S3 Appendix.
323
The plots in Fig 4a show the changes in concentration of drug within the blood plasma 324 over a short time-range (t=5 to t=25). There, C pl is plotted along the capillaries Table 2 . a) The pathway from U in to U out along which C pl is plotted. b) C pl is plotted against time (timepoints from 5 to 25) along the distance shown in (a). c) Distribution profiles of C pl (red) and C ECF (blue) of the 3D brain unit at t=5. Darker shades of red and blue correspond to higher values of C pl and C ECF, respectively. Fig 5. The effect of active influx on the log concentration-time profiles of drug in the brain ECF, relative to those in the blood plasma. Top: unbound drug in the brain ECF (C ECF) compared to unbound drug in the blood plasma (C pl , red curve). Middle: drug bound to its target sites (B 1). Bottom: drug bound to non-specific binding sites (B 2). The value of T m-in is changed from 0 to 100·10 -7 µmol s -1 . The rest of the parameters are as in Table 2 .
differences in C pl become small relative to the value of C pl . Fig 4c shows the 332 distribution profiles of unbound drug within the 3D brain unit at t=5 for different 333 values of v blood . There, darker shades of red and blue correspond to higher 334 concentrations of unbound drug in the blood plasma and the brain ECF, respectively.
335
When v blood =0.5·10 -4 m s -1 , the transport time of drug between U in and the opposite 336 corner is higher than when v blood =5·10 -4 m s -1 . This is depicted in Fig 4c, (v blood =5·10 -4 m s -1 and v blood =50·10 -4 m s -1 ), C ECF at t=5 is overall higher, but 343 again highest in the corner close to U in . binding sites are saturated. We find that 90% max(B 1 ) is attained longer for a higher 356 T m-in . Fig 5 (bottom) shows that higher values of T m-in correlate with higher values of 357 B 2 and thus a greater occupancy of non-specific binding sites. The non-specific binding 358 sites within the brain ECF become saturated with drug when T m-in is sufficiently high 359 (T m-in =100·10 -7 µmol s -1 ). To evaluate the effect of active efflux on drug concentrations 360 within the brain ECF, we repeat our simulations with T m directed outward, i.e. with 361 T m-out =0-100·10 -7 µmol s -1 and T m-in =0. Fig 6 (top) shows that C ECF decreases faster 362 for higher values of T m-out , corresponding to more active efflux. Fig 6 ( Fig 6. The effect of active efflux on the log concentration-time profiles of drug in the brain ECF, relative to those in the blood plasma. Top: unbound drug in the brain ECF (C ECF) and unbound drug in the blood plasma (C pl , red curve). Middle: drug bound to its target sites (B 1). Bottom: drug bound to non-specific binding sites (B 2). The value of T m-out is changed from 0 to 100·10 -7 µmol s -1 . The rest of the parameters are as in Table 2 . Table 2. 3.3 The effect of the brain capillary blood flow velocity in the 368 presence of active transport 369
In section 3.1 we have shown that both the passive BBB permeability, P, and the brain 370 capillary blood flow velocity, v blood , affect dug brain ECF PK in the absence of active 371 transport. Here, we study how P and v blood combined with active transport affect drug 372 PK within the brain ECF. (Fig 7, 379  right) . When the BBB is very permeable, active influx needs to be fast to have any 380 effect, as drug can easily pass the BBB to flow back into the blood plasma. As shown in 381 Fig 7, right, in the presence of a high value of P, T m-in only (slightly) affects C ECF 382 when it is 10·10 -7 µmol s -1 or higher. affect the impact of T m-out on C ECF . If P is high, drug can easily flow across the BBB 389 back into the brain ECF, following the concentration gradient between the blood 390 plasma and the brain ECF, thereby countering the effect of T m-out . Fig 8 (top right) 
391
shows that for a high P, C ECF is only affected by T m-out when its value is higher than 392 10·10 -7 µmol s -1 . The values of C ECF in the presence of active efflux and a high passive 393 BBB permeability, P, are unaffected by v blood (Fig 8, right) .
394
Next, we study how the drug distribution within the 3D brain unit is affected by v blood , 395 P, T m-in and T m-out . Fig 9 shows cross-sections (for y= 1 2 y r and z=0) of the 3D brain The rest of the parameters are as in Table 2 . Fig 9. The distribution profiles at cross-sections (at y= 1 2 yr) of the 3D brain unit at t=5 of unbound drug in brain ECF with lower brain capillary blood flow velocity (v blood =0.5·10 -4 m s -1 , middle column), higher passive BBB permeability (P =100·10 -7 m s -1 , right column), presence of active influx (middle row, T m-in=1·10 -7 µmol s -1 ) and presence of active efflux (bottom row, T m-out=1·10 -7 µmol s -1 ) at t=5. Parameters are as in Table 2 . µmol s -1 ) at different locations. When T m-in is changed, T m-out=0 and vice versa. c) Colour legend. In each table, colours are relative to the value of C ECF in the middle of the unit in the absence of active transport for v blood =5·10 -4 m s -1 , of which the colour is denoted by "Default". The intensity of green corresponds to the extent of increase, and the intensity of red corresponds to the extent of decrease of C ECF compared to the default. Other parameters are as in Table 2 .
indicate higher concentrations. In Fig 9a (left) we give a plot for a default P and v blood 399 (Fig 9a, left) . Then, we decrease v blood (Fig 9a, middle) or increase P (Fig 9a, right) .
400
For a lower v blood , relative differences of C pl over space increase (Fig 9a, middle) .
401
Additionally, due to the decrease in C pl , local differences in C ECF become more 402 apparent. A larger value of P results in an increased exchange of drug between the 403 blood plasma and the brain ECF, such that C ECF becomes higher (Fig 9a, right) . value of v blood , local differences in U pl become apparent (Fig 9b, middle) . Finally, Fig 407  9c shows that with active efflux, C ECF becomes smaller than when no active efflux is 408 present, except for when P is high and more pronounced. within the 3D brain unit more clearly. There, values of C ECF are given for four different 411 locations within the 3D brain unit for several values of v blood and P and t=500. The 412 table again (as in Fig 7, 8 and 9 ) shows that v blood and P affect the impact of T m-in 413 and T m-out on C ECF . It provides additional information on the distribution of C ECF 414 within the 3D brain unit. In general, C ECF is higher in the corners relative to the edge 415 and middle within the 3D brain unit. The extent of these local concentration differences 416 depends on the values of T m-in and T m-out . The differences are largest when 417 T m-out =1·10 -7 µmol s -1 , depicted in the lowest line of each sub- We have developed a mathematical model that describes the local distribution of a drug 423 within a 3D brain unit as an extension of our earlier 2D proof-of-concept model [29] .
424
The 3D brain unit is represented as a cube. This new model provides an important step 425 towards more realistic features of the brain. The 3D representation allows for the active transport across the BBB have been explicitly incorporated. This enables us to 428 more realistically predict the impact of the interplay of cerebral blood flow, BBB 429 characteristics, brain ECF diffusion, brain ECF bulk flow and brain (target) binding on 430 drug distribution within the brain. Altogether our model allows the study of the effect 431 of a large amount of parameters values (summarized in Table 1 ) on drug distribution 432 within the 3D brain unit.
433
This study has focused on the effect of the newly implemented brain properties on brain 434 ECF concentrations a drug within the brain. It is shown that the brain capillary blood 435 flow velocity and the passive BBB permeability affect the concentration of a drug 436 within the brain, and, as anticipated [68, 69] that a low brain capillary blood flow 437 velocity affects the short-term, but not the long-term concentration-time profiles of C pl 438 and C ECF , (Fig 3 and 4) . Also, passive BBB permeability has a high impact on brain 439 ECF PK, even when drug is actively transported across the BBB. Moreover, the BBB 440 permeability and, in smaller extent, the brain capillary blood flow velocity affect the 441 impact of active influx on drug PK within the brain ECF (Fig 7 and 8) . Interestingly, 442 the brain capillary blood flow velocity, passive BBB permeability and active transport 443 do not only affect the concentration of drug within the brain ECF, but also its 444 distribution within the brain ECF (Fig 9 and 10 .
445
Taken together, the 3D brain unit model shows the impact of drug-specific and 446 brain-specific parameters on drug distribution within the brain ECF. The added value is 447 that all these factors can now be studied in conjunction to understand the 448 interdependencies of multiple brain parameter values and drug properties. This makes 449 this single 3D brain unit model suitable for the next step, which is to mount up multiple 450 units to represent a larger volume of brain tissue, in which the brain tissue properties 451 for each unit can be defined independently. The units may be given different systemic 452 properties (such as the BBB permeability or drug target concentration), to represent 453 the heterogeneity of the brain in a 3D manner. 454 S1 Appendix -Nondimensionalization of the model 455 We can make Eq (2-16) dimensionless by introducing a change of variables. Here, the original variables are scaled to dimensionless variables by scaling with a characteristic, dimensional scale. We set:
, and the following system of dimensionless equations for drug within the brain ECF (for Eq (6)):
The corresponding boundary conditions (Eq (10)-(11), example for Eq (10), but similar 456 for Eq (10)) are given by: S2 Appendix-The effect of paracellular permeability 459 on PK within the brain ECF 460 We study the passive transcellular permeability and passive paracellular permeability 461 separately. This is different from before, where we have studied the total passive 462 permeability. We study the effect of paracellular transport on the PK within the 3D 463 brain unit. The paracellular permeability can increase due to disruption of the BBB, 464 which in turn could be a result of disease. We include paracellular permeability and 465 study its effect on drug concentrations within the 3D brain unit. For drugs for which 466 the passive transcellular BBB permeability is low (P trans =0.01·10 -7 µmol s -1 ), Supplementary Figure 3 . The effects of v blood on k BBB . The effect of v blood on k BBB depends on P. Note that here P is taken 10 3 times its default value, see Table 2 .
Box I -The Renkin-Crone equation
The brain capillary blood flow affects the passive clearance of a drug across the BBB according to the Renkin-Crone equation [64, 65] . The Renkin-Crone equation describes the relation between the brain capillary blood flow and transport across the BBB as follows:
, with K in the passive clearance of drug from the blood into the brain (L s -1 ), Q (L s -1 ) the blood flow rate in the brain capillaries and PS (L s -1 ) the passive permeability surface of the BBB. Both Q and PS have the same units, such that, E, the ratio of compound extracted from the blood into the brain, is dimensionless.
The Renkin-Crone equation shows that the transport from the blood into the brain depends on the ratio of the BBB permeability surface (PS ) and the blood flow rate (Q). When PS Q, the extraction ratio E approaches 1, such that K in is determined by changes in Q. In other words, when PS Q, drug transport across the BBB is much faster than the rate of drug supply into the brain capillaries. Then, drug transport into the brain can only be increased by increasing Q. On the other hand, when Q PS, E approaches 0. In this case, the drug supply into the brain capillaries is much faster than the rate of drug transport across the BBB. Then, drug transport into the brain can only be increased by increasing PS. The Renkin-Crone equation implies that the effect of the brain capillary blood flow rate on the concentration of unbound drug exchanging with the brain is most pronounced for drugs that easily cross the BBB [65, 70] , i.e. drugs for which PS Q, or, in terms of velocity rather than rate, drugs for which P v blood . Under general, non-pathological circumstances v blood is around 5·10 -4 m s -1 (see Tables 1  and 2 ), which implies that BBB transport is impacted by the blood flow velocity when drug molecules have a value of P that is (much) higher than 10 -4 m s -1 (i.e. 10 3 times the default value as given in Table 2 ).
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